Cargando…

Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy

Cusatuzumab is a high-affinity, anti-CD70 monoclonal antibody under investigation in acute myeloid leukemia (AML). This two-part, open-label, multicenter, phase I/II trial evaluated cusatuzumab plus azacitidine in patients with newly diagnosed AML ineligible for intensive chemotherapy. Patients rece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pabst, Thomas, Vey, Norbert, Adès, Lionel, Bacher, Ulrike, Bargetzi, Mario, Fung, Samson, Gaidano, Gianluca, Gandini, Domenica, Hultberg, Anna, Johnson, Amy, Ma, Xuewen, Müller, Rouven, Nottage, Kerri, Papayannidis, Cristina, Recher, Christian, Riether, Carsten, Shah, Priya, Tryon, Jeffrey, Xiu, Liang, Ochsenbein, Adrian F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Article - Acute Myeloid Leukemia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316251/ https://www.ncbi.nlm.nih.gov/pubmed/36779592 http://dx.doi.org/10.3324/haematol.2022.281563

Ejemplares similares

Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens
por: Jensen, Christopher E., et al.
Publicado: (2022)

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
por: Gutman, Jonathan A., et al.
Publicado: (2023)

AML-168: The Assessment of COVID-19 Evolution in Patients with Oncological Diseases Admitted in an Intensive Care Unit of One Romanian Center
por: Popov, Viola Maria, et al.
Publicado: (2021)

AML-145: Outcomes of Induction Therapy in Patients with Acute Myeloid Leukemia During Covid-19 Pandemic: A Retrospective Study from a Tertiary Care Cancer Centre
por: Iqbal, Asif, et al.
Publicado: (2021)

AML-355: Incidence and Severity of COVID-19 among Inpatients with Hematologic Malignancies
por: Wozniaki, Natalia, et al.
Publicado: (2021)

AML-075: Converting In-Person Research Procedures to a Virtual Platform During the COVID-19 Pandemic in Newly Diagnosed Acute Myeloid Leukemia Patients
por: Tinsley, Sara, et al.
Publicado: (2021)

Acute myeloid leukemia
por: Haferlach, Torsten
Publicado: (2019)

The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias
por: Paolillo, Rosa, et al.
Publicado: (2022)

Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill F LT 3-ITD acute myeloid leukemia
por: Post, Sean M., et al.
Publicado: (2021)

A risk score based on real-world data to predict early death in acute promyelocytic leukemia
por: Österroos, Albin, et al.
Publicado: (2022)

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
por: Russell, Nigel H., et al.
Publicado: (2021)

The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements
por: Grasedieck, Sarah, et al.
Publicado: (2021)

Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy
por: Ihlow, Jana, et al.
Publicado: (2021)

A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo
por: Arruda, Lucas C. M., et al.
Publicado: (2022)

A self-assembled leucine polymer sensitizes leukemic stem cells to chemotherapy by inhibiting autophagy in acute myeloid leukemia
por: Xu, Xi, et al.
Publicado: (2022)

Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children’s Oncology Group study
por: Hoff, Fieke W., et al.
Publicado: (2022)

Meis1 supports leukemogenesis through stimulation of ribosomal biogenesis and Myc
por: Garcia-Cuellar, Maria-Paz, et al.
Publicado: (2022)

Pseudo-mutant P53 is a unique phenotype of DNMT3A-mutated pre-leukemia
por: Tuval, Amos, et al.
Publicado: (2022)

Persistent DNA damage and oncogenic stress-induced Trem1 promotes leukemia in mice
por: Li, Xue, et al.
Publicado: (2022)

Interplay between hypertriglyceridemia and acute promyelocytic leukemia mediated by the cooperation of peroxisome proliferator-activated receptor-α with the PML/RAR α fusion protein on super-enhancers
por: Wu, Shishuang, et al.
Publicado: (2022)

Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data
por: Othus, Megan, et al.
Publicado: (2022)

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4
por: Kayser, Sabine, et al.
Publicado: (2022)

Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia
por: Sourdeau, Elise, et al.
Publicado: (2022)

COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
por: Marchesi, Francesco, et al.
Publicado: (2022)

Analysis of rare driving events in pediatric acute myeloid leukemia
por: Noort, Sanne, et al.
Publicado: (2022)

Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial
por: Buccisano, Francesco, et al.
Publicado: (2022)

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia
por: Orvain, Corentin, et al.
Publicado: (2022)

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
por: Pratz, Keith W., et al.
Publicado: (2022)

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications
por: Nilsson, Christer, et al.
Publicado: (2022)

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy
por: Zhang, Weiguo, et al.
Publicado: (2022)

Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation
por: Yerushalmi, Yaara, et al.
Publicado: (2022)

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2022)

Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia
por: Sahoo, Binay K., et al.
Publicado: (2022)

Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells
por: Jia, Yannan, et al.
Publicado: (2023)

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2023)

Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity
por: O’Brien, Cristiana, et al.
Publicado: (2023)

Cellular and metabolic characteristics of pre-leukemic hematopoietic progenitors with GATA2 haploinsufficiency
por: Rein, Avigail, et al.
Publicado: (2022)

Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine
por: Assouline, Sarit, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3t6ud5v49ag8lu518qg9u9sck5